{"entity":{"id":"bmt-ctn-0803","kind":"trial","name":"BMT CTN 0803","aka":["BMTCTN0803","CTN 0803","AMC 071"],"tldr":"BMT CTN 0803 showed that people living with HIV whose lymphoma had come back can have the same high-dose chemotherapy and stem cell transplant as anyone else, with 87 percent alive at one year and outcomes no different from matched HIV-negative patients, so HIV alone should not bar transplant.","summary":"BMT CTN 0803/AMC 071 was a single-arm phase 2 trial of the Blood and Marrow Transplant Clinical Trials Network and the AIDS Malignancy Consortium in 43 HIV-infected patients with chemotherapy-sensitive relapsed or persistent aggressive B-cell or Hodgkin lymphoma; 40 underwent autologous transplant after BEAM conditioning with protocol-defined management of antiretroviral therapy around transplant. The primary endpoint was one-year overall survival.\n\nAt a median follow-up of 24.8 months, one- and two-year overall survival were 87.3 and 82 percent, two-year progression-free survival 79.8 percent and one-year transplant-related mortality 5.2 percent; engraftment was prompt and outcomes did not differ from 151 matched HIV-negative registry controls. The corpus's HIV-associated lymphoma page cites BMT CTN 0803 for autologous transplant being feasible with controlled HIV.","status":"positive","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT01141712","url":"https://clinicaltrials.gov/study/NCT01141712"}],"tags":["soc-trials"],"related":[],"cancers":["hiv-associated-lymphoma","non-hodgkin-lymphoma","hodgkin-lymphoma"],"sections":[],"technologies":["autologous-stem-cell-transplant","cytotoxic-chemotherapy"],"targets":[],"drugs":["carmustine","etoposide","cytarabine","melphalan"],"companies":[],"institutions":["mcw-cancer-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-bmt-ctn-0803-autologous-transplant-hiv-lymphoma-alvarnas-blood-2016"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01141712","phase":"2","setting":"HIV-infected patients over 15 with chemotherapy-sensitive relapsed or persistent aggressive B-cell lymphoma or Hodgkin lymphoma and treatable HIV: high-dose carmustine, etoposide, cytarabine and melphalan (BEAM) with autologous stem cell transplant and consistent peri-transplant antiretroviral management","sponsor":"Medical College of Wisconsin","result":"One-year overall survival 87.3 percent and two-year overall survival 82 percent after autologous transplant, with two-year progression-free survival 79.8 percent and one-year transplant-related mortality 5.2 percent, no different from matched HIV-negative controls.","yearReported":2016,"enrolled":43,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall survival at 1 year","primary":true,"unit":"%","arms":[{"name":"BEAM and autologous transplant in HIV-infected patients","n":40,"value":87.3,"note":"95% CI 72.1 to 94.5; 43 enrolled, 40 transplanted"}],"source":"https://doi.org/10.1182/blood-2015-08-664706"},{"endpoint":"Overall survival at 2 years","unit":"%","arms":[{"name":"BEAM and autologous transplant in HIV-infected patients","n":40,"value":82,"note":"95% CI 65.9 to 91"}],"source":"https://doi.org/10.1182/blood-2015-08-664706"},{"endpoint":"Progression-free survival at 2 years","unit":"%","arms":[{"name":"BEAM and autologous transplant in HIV-infected patients","n":40,"value":79.8,"note":"95% CI 63.7 to 89.4"}],"source":"https://doi.org/10.1182/blood-2015-08-664706"},{"endpoint":"Transplant-related mortality at 1 year","unit":"%","arms":[{"name":"BEAM and autologous transplant in HIV-infected patients","n":40,"value":5.2}],"source":"https://doi.org/10.1182/blood-2015-08-664706"}]},"route":"/trials/bmt-ctn-0803/","neighbours":{"cancer":[{"id":"hiv-associated-lymphoma","kind":"cancer","name":"HIV-associated (AIDS-related) lymphomas","route":"/cancers/hiv-associated-lymphoma/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"technology":[{"id":"autologous-stem-cell-transplant","kind":"technology","name":"Autologous stem cell transplant (high-dose therapy)","route":"/technologies/autologous-stem-cell-transplant/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"carmustine","kind":"drug","name":"Carmustine","route":"/drugs/carmustine/"},{"id":"cytarabine","kind":"drug","name":"Cytarabine","route":"/drugs/cytarabine/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"},{"id":"melphalan","kind":"drug","name":"Melphalan (including hepatic delivery system)","route":"/drugs/melphalan/"}],"institution":[{"id":"mcw-cancer-center","kind":"institution","name":"Medical College of Wisconsin Cancer Center","route":"/institutions/mcw-cancer-center/"}],"paper":[{"id":"paper-bmt-ctn-0803-autologous-transplant-hiv-lymphoma-alvarnas-blood-2016","kind":"paper","name":"BMT CTN 0803/AMC 071: autologous haematopoietic cell transplantation for HIV-related lymphoma","route":"/key-papers/paper-bmt-ctn-0803-autologous-transplant-hiv-lymphoma-alvarnas-blood-2016/"}]}}